Alnylam Pharmaceuticals : 2023 REPORT

Corporate

Responsibility

Report 2023

2022 ESG REPORT	Introduction	Patients	Science	Employees	Communities	Planet	Governance	Data
Corporate Responsibility Report 2023

Table of

Contents

3 CEO Letter

1. About Alnylam
2. 2023 Highlights
3. Corporate Responsibility at Alnylam

1. Patients

1. Science

1. Employees

1. Communities

1. Planet

1. Governance

1. Data Summary

On the Cover: Saint, patient with his son/caregiver, U.K.

2022 ESG REPORT	Introduction	Patients	Science	Employees	Communities	Planet	Governance	Data
Corporate Responsibility Report 2023

CEO Letter

"To be successful, we must scale sustainably so that we are considerate of the environment while also engaging with the communities in which we operate."

Alnylam continues to lead the wave of RNAi innovation that is changing medicine. I am so excited about our future and the enormous promise we hold to improve the lives of patients around the world. As we grow and progress in our quest to build the next great biotechnology company, we continue to expand our leadership and impact as a responsible corporate citizen, highlighted by our work in four key areas:

Ensuring Access to Our Medicines

Our deep commitment to patients is reflected in our Patient Access Philosophy, the set of core principles that have guided us in our efforts to discover and develop new medicines. It articulates our fundamental commitment to ensuring broad access to these medicines, improving health outcomes for patients, and increasing the value that we provide to society. Our Patient Access Philosophy has been our guide since Alnylam's earliest days. In 2024, we will relaunch our Patient Access Philosophy, retaining our committment to proactivity, collaboration and accountability, while leaning in to the responsbility we have as a biopharmaceutical company in the patient journey to innovative therapeutic options.

Investing in Our People and Culture

If we want to embrace disruption and drive innovation, we need a diverse group of people who can think critically, ask tough questions, and challenge the status quo. Our employees embody these attributes and continuously raise the bar on what we can achieve together. Alnylam is for people who want to make an impact; our team is encouraged to set big goals, advance our culture of integrity, continuously learn, and build fulfilling, long-term careers. Throughout this report, you'll see the evidence of this work in our recognition as a "Best Place to Work" by multiple sources globally, including receiving the #1 ranking for the 'Largest Employer' category from The Boston Globe for the third year in a row.

3

2022 ESG REPORT	Introduction	Patients	Science	Employees	Communities	Planet	Governance	Data
Corporate Responsibility Report 2023

Mitigating Our Environmental Impact

To be successful, we must scale sustainably so that we are considerate of the environment while also engaging with the communities in which we operate. Throughout our manufacturing operations, we carefully consider energy, water usage, and waste disposal, and over the last five years we have established new systems to measure, assess, report on, and mitigate our greenhouse gas emissions globally. This year, we made progress by sourcing renewable energy for our Norton and Alewife facilities where we have complete operational control. This is just one step along our continued sustainability journey.

Engaging in Our Communities

As our business and therapeutic pipeline expands, we are simultaneously increasing our investment in communities. We support initiatives and programs that envision a future where health equity

is realized for all people served by our industry. At Alnylam, we are actively working to develop innovative health equity community partnerships designed to address unique societal challenges and individual needs.

In our 2023 Corporate Responsibility Report, you will see the hard work and accomplishments of teams across Alnylam this past year. We are proud to share the steps we have taken to build a healthier, more resilient path forward. In the coming years, we will continue to challenge ourselves, pioneering and pushing ahead. Advancing innovations in medicines, advocacy, and access to care that ensures global health equity is possible. I hope you will join us in creating history together.

Sincerely,

Yvonne Greenstreet, MBChB

Chief Executive Officer

"

As our business and therapeutic pipeline expands, we are simultaneously increasing our investment in communities. We support initiatives and programs that envision a future where health equity is realized for all people served by our industry.

"

4

2022 ESG REPORT

Corporate Responsibility Report 2023

Introduction	Patients	Science	Employees	Communities	Planet	Governance	Data

About Alnylam

Alnylam was founded in 2002 and since then has led the RNAi RevolutionTM, translating the Nobel Prize-winning discovery of RNA interference (RNAi) into an innovative new class of medicines that is changing the way that disease is treated and improving lives around the world.

"

We are working hard to bring the next wave of RNAi innovations to transform the lives of patients everywhere.

"

Kevin Fitzgerald

PhD, Chief Scientific Officer

Alnylam's RNAi Therapeutics

RNAi therapeutics silence the genes that cause or contribute to diseases. They represent an innovative, clinically- validated approach to treating both rare and prevalent diseases. Our breakthrough RNAi science has moved from discovery to innovation, growing in its positive impact on

2019 GIVLAARI® (givosiran) The first approved treatment for acute hepatic porphyria (AHP) in adults.

ONPATTRO® (patisiran)

2022

OXLUMO® (lumasiran)

AMVUTTRA® (vutrisiran)

Treats the polyneuropathy caused by hereditary ATTR (hATTR) amyloidosis in adults.

global health every year.

Treats the polyneuropathy caused by	2020
2018 hereditary ATTR (hATTR) amyloidosis.

The first approved treatment for infants, children, and adults with primary hyperoxaluria type 1 (PH1) via sub-cutaneous injection.

5

2022 ESG REPORT	Introduction	Patients	Science	Employees	Communities	Planet	Governance	Data
Corporate Responsibility Report 2023

Alnylam's growth is

2023 BY THE NUMBERS

guided by our P5x25 global strategy:

• Patients: Over 0.5 million on Alnylam RNAi medicines globally
• Products: 6+ marketed products in rare and prevalent diseases
• Pipeline: Over 20 clinical programs, with 10+ in late stages and 4+ INDs per year
• Performance: ≥40% revenue CAGR through YE 2025
• Profitability: Achieve sustainable non-GAAP profitability within the period

5 approved products - 4 wholly owned, and Leqvio® (inclisiran) through a licensing and collaboration agreement with Novartis

$1.24+

billion in annual product revenue in 2023

39%

year-over-year growth in total net product revenues

15 programs in clinical development, including 4 in late-stage development

5,100+

patients enrolled on commercial therapy globally

60+

countries with commercial presence (direct or through distributor)

6

Corporate Responsibility Report 2023	Introduction	Patients	Science	Employees	Communities	Planet	Governance	Data

Corporate Responsibility

at Alnylam

Our "Challenge Accepted" ethos at Alnylam extends beyond our therapies. It is accompanied by a responsibility to be an ethical, values-based corporate citizen, which frames our approach to Corporate Responsibility (CR) across Alnylam.

Corporate Responsibility at Alnylam centers around a global theme: "Accepting Challenges to Improve the Health of Humanity." This theme informs our business strategy and how Alnylam operates across closely interrelated pillars material to our everyday operations and external impact - Patients, Science, Employees, Communities, Planet, and Governance.

We recognize that addressing health inequities and removing barriers to medicines and healthcare is a core part of our business and is thus embedded throughout our CR initiatives. Together we can unleash the power of pioneering science, entrepreneurial ideas, and social investments to improve health outcomes for all by advancing innovations in medicines and access to care.

7

2022 ESG REPORT

Corporate Responsibility Report 2023

Introduction	Patients	Science	Employees	Communities	Planet	Governance	Data

B E L I E F S

We believe in the noble pursuit of working to improve the health of humanity.

We believe science has the power to solve many complex social, health, and environmental challenges.

We believe diverse, inclusive, and equitable environments are essential for achieving breakthroughs.

We believe all communities deserve access to health solutions and social supports.

ALNYLAM'S CR OPERATING MODEL

P I L L A R S

SCIENCE

	We advocate
	for science and
	innovation to address
GOVERNANCE	critical health and	PATIENTS
social issues.	We strive to improve
We set high standards
	patients' lives and enable
for our employees
	access to potentially
and partners.
	life-changing treatments.

PLANET		EMPLOYEES
We seek to improve		We foster an open,
	diverse culture where
the health and
	employees feel
sustainability of
COMMUNITIES	included, supported
our planet.
	We actively engage	and heard.
	people in tackling the
	world's most pressing
	community and health
	equity challenges.

H E A LT H E Q U I T Y

P R I N C I P L E S

Strategy: Integrating health equity considerations throughout our business operations.

Science: Advancing new medicines and innovations that increase accessibility and efficacy.

Advocacy: Using our leadership platform to raise awareness and amplify patient voices.

Collaboration: Working together with payors, providers, governments, regulators, patient advocacy organizations, distribution partners, and other global stakeholders to develop systemic solutions that remove barriers to care.

Empathy: Ensuring our culture and employees are inclusive and responsive to the needs of patients.

Innovation: Empowering innovators and social sector organizations to address the specific needs of targeted populations.

8

2022 ESG REPORT	Introduction	Patients	Science	Employees	Communities	Planet	Governance	Data
Corporate Responsibility Report 2023

•

Understanding

MATERIALITY MATRIX

Material Topics

In 2021, Alnylam completed our first multi-faceted materiality assessment to identify the topics in CR and ESG (environmental, social, governance) that aligned with our CR Pillars globally.

We also considered Alnylam's business imperatives and focus areas related to our P5X25 strategy in this process. In 2023, we revisited our materiality assessment to ensure the topics we identified in 2021 remain relevant.

As a result, we have added topics, including energy management, to our materiality matrix. In 2024 and 2025, we will prepare to meet the requirements of the Corporate Sustainability Reporting Directive (CSRD) and, as a part of this process, continue to refine our materiality assessment to include the principles of double materiality. Our CR Steering Committee will oversee this process and will continue to form the structure of our annual CR reporting, key performance indicators, and targets.

C R P I L L A R

Patients

Science

Employees

Communities

Planet

Governance

M AT E R I A L TO P I C S

Patient engagement and education Equitable access and affordability Patient health outcomes

Clinical trial practices Product quality and safety

R&D, innovation, and product pipeline

Workplace culture

Diversity, equity, and inclusion Occupational health and safety Talent attraction and retention

Community impact

Health equity

STEM education

Climate change

Energy

Waste management

Water and wastewater

Corporate Governance

Transparency

Supplier responsibility

Data security and privacy

9

Corporate Responsibility Report 2023	Introduction	Patients	Science	Employees	Communities	Planet	Governance	Data

About This Report

Our CR Steering Committee and the CR Working Groups focused on each of our major CR pillars have overseen the creation

of our 2023 Corporate Responsibility Report. Together, these teams have set targets, reflected on previous years' targets, and enhanced our goals and key performance indicators to track our performance in Corporate Responsibility.

This report is framed around our CR pillars and the topics within those pillars identified in our 2021 materiality assessment. In 2023, Alnylam conducted a refresh of our materiality assessment to ensure these topics remained relevant to our current reporting. In 2023, we continued to prepare our report in accordance with the Global Reporting Initiative (GRI) Standards: Core option and the Sustainability Accounting Standards Board (SASB) Biotechnology

• Pharmaceuticals Standard. The Scope 1 and 2 GHG Inventory included in this report has been independently verified at the Limited Assurance level by Cameron-Cole based on the World Resources Institute (WRI)/World Business Council for Sustainable Development (WBCSD) Greenhouse Gas Protocol.
  A complete verification statement can be found here.

We also recognize our work in CR aligns with numerous UN Sustainable Development Goals (SDGs) which serve as a global framework for global partnership to improve health and education, spur economic growth, and focus on diminishing the effects of climate change. Our business goals and the goals of our CR programs globally align most directly with the following UN SDGs:

Our RNAi therapeutics have	Every biotech leader must	We are consistently working	We are working to calculate
the potential to positively	work to bring the pipeline of	to improve our environmental	emissions and set our
impact patients around	medicines to a larger global	footprint to diminish energy,	first global target for GHG
the world.	market. Our focus on both rare	water and materials use	emission reduction across
	and prevalent diseases begins	across our supply chain.	our operations. This, along
	with R&D and continues		with our forward-thinking
	through our manufacturing		environmental actions inside
	and distribution processes.		our facilities, help to combat
			climate change globally.

Alnylam Forward Looking Statements

This report contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. All statements other than historical statements of fact regarding Alnylam's expectations, beliefs, goals, plans or prospects including, without limitation, statements regarding Alnylam's aspiration to become a top-tier biotech company, the potential for Alnylam to identify new potential drug development candidates and advance its research and development programs, Alnylam's ability to obtain approval for new commercial products or additional indications for its existing commercial products, the goals and priorities of Alnylam's corporate responsibility programs and reporting of its corporate responsibility-related metrics, and the planned achievement of its "Alnylam P5x25" strategy, should be considered forward-looking statements. Actual results and future plans may differ materially from those indicated by these forward-looking statements as a result of various important risks, uncertainties and other factors, including, without limitation, risks and uncertainties relating to: Alnylam's ability to successfully execute on its "Alnylam P5x25" strategy; Alnylam's ability to discover and develop novel drug candidates and delivery approaches and successfully demonstrate the efficacy and safety of its product candidates; the pre-clinical and clinical results for Alnylam's product candidates, including vutrisiran, zilebesiran, and mivelsiran; actions or advice of regulatory agencies and Alnylam's ability to obtain and maintain regulatory approval for its product candidates, including vutrisiran, as well as favorable pricing and reimbursement; successfully launching, marketing and selling Alnylam's approved products globally; delays, interruptions or failures in the manufacture and supply of Alnylam's product candidates or its marketed products; obtaining, maintaining and protecting intellectual property; Alnylam's ability to successfully expand the approved indications for AMVUTTRA in the future; Alnylam's ability to manage its growth and operating expenses through disciplined investment in operations and its ability to achieve a self-sustainable financial profile in the future without the need for future equity financing; the direct or indirect impact of any future pandemic on Alnylam's business, results of operations and financial condition; Alnylam's ability to maintain strategic business collaborations; Alnylam's dependence on third parties for the development and commercialization of certain products, including Roche, Novartis, Sanofi, Regeneron and Vir; the outcome of litigation; the risk of future government investigations; unexpected expenditures; and changes in the legal and regulatory environment, including environmental, health and safety laws and regulations; as well as those risks and uncertainties more fully discussed in the "Risk Factors" filed with Alnylam's 2023 Annual Report on Form 10-K filed with the Securities and Exchange Commission (SEC), as may be updated from time to time in Alnylam's subsequent Quarterly Reports on Form 10-Q, and in other filings that Alnylam makes with the SEC. In addition, any forward-looking statements represent Alnylam's views only as of today and should not be relied upon as representing its views as of any subsequent date. Alnylam explicitly disclaims any obligation, except to the extent required by law, to update any forward-looking statements.

10